Upcoming Webinar :Register now for 'ULIP as an investment during economic recovery' powered by Bajaj Allianz Life Insurance
you are here: HomeNewsBusiness

India struggles with excess supply of masks, 50% of companies may shut: Report

Not only inventories, but underutilised plants and machinery are also India’s concern.

December 14, 2020 / 02:23 PM IST
File image of an N95 mask

File image of an N95 mask

India has managed to flip the supply situation on face masks, going from suffering a shortage of the product to now having surplus stock of surgical and N95 masks.

The oversupply is such that at least 50 percent of companies engaged in the business will likely down shutters – some already have plans to do so, as per a Times of India report.

Experts told the paper that “unethical market practices, poor domestic demand and red-tapism” has reduced capacity utilisation to just one-third.

Moneycontrol could not independently verify the report.

Follow our LIVE Updates on the coronavirus pandemic here

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

“Production capacity for N95 masks is 20 crore units per month, while the utilisation is merely 10 percent. Similarly for surgical masks, capacity is more than 60 crore units/month of which only 30 percent is used,” Anshumali Jain, president of the All India Mask Manufacturers Association told the paper.

Experts added that high demand and low availability of masks at the beginning of the pandemic led new entrants into the segment, while existing players expanded production in April-June, on hopes that demand would continue to be high.

“Established players were able to use their full capacity for a brief time, but once exports were banned, demand started dropping drastically, and supply kept getting created just as fast, resulting in extreme oversupply,” Jain added.

Not only inventories, but underutilised plants and machinery are also a concern.

Check here for the latest updates on all COVID-19 vaccines

The ban on export of masks was imposed in March to ensure adequate domestic supply of masks amid increasing cases. This was lifted for 3-ply masks in August, but India missed the boat to become the export hub by then and the industry had become more competitive.

The ban on export of N95 masks was only lifted in October – which was also too late, noted Rajiv Nath, forum coordinator of industry body AiMeD. “Many manufacturers are now struggling to sell finished goods, or even raw materials' inventory, below costs to create cash flow. It's survival of the fittest, and those who can export surplus capacity,” he added.

Other factors were the government’s encouragement of ‘gamcha’ (thin towels) as a substitute for masks, cheap Chinese options flooding the market in June and government advisory on valved respirators which hit demand for N95 masks, the report said.

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Dec 14, 2020 02:23 pm

stay updated

Get Daily News on your Browser
Sections